ID: ALA289613

Max Phase: Preclinical

Molecular Formula: C42H47N3O6

Molecular Weight: 689.85

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCCCOc2cc(C(=O)c3cn(CCCC(=O)O)c4ccccc34)ccc2OCc2ccc(C)cc2)CC1

Standard InChI:  InChI=1S/C42H47N3O6/c1-31-15-17-32(18-16-31)30-51-39-20-19-33(42(48)35-29-45(22-9-14-41(46)47)36-11-4-3-10-34(35)36)28-40(39)50-27-8-7-21-43-23-25-44(26-24-43)37-12-5-6-13-38(37)49-2/h3-6,10-13,15-20,28-29H,7-9,14,21-27,30H2,1-2H3,(H,46,47)

Standard InChI Key:  JJRGSYIIOKDBJX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 689.85

Molecular Weight (Monoisotopic): 689.3465

AlogP: 7.61

#Rotatable Bonds: 17

Polar Surface Area: 93.47

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.83

CX Basic pKa: 7.32

CX LogP: 5.18

CX LogD: 4.92

Aromatic Rings: 5

Heavy Atoms: 51

QED Weighted: 0.08

Np Likeness Score: -1.00

References

1. Sato H, Kitagawa O, Aida Y, Chikazawa J, Kurimoto T, Takei M, Fukuta Y, Yoshida K..  (1999)  Dual-acting agents with alpha1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory activities. Synthesis and evaluation of arylpiperazine derivatives.,  9  (11): [PMID:10386934] [10.1016/s0960-894x(99)00230-9]

Source

Source(1):

• Scientific Literature